Adrenocortical carcinoma is a rare malignancy with a poor prognosis. The effective treatment for advanced cancer remains unknown. A 61-year-old woman underwent CyberKnife treatment on a large adrenocortical carcinoma and tumor emboli in both pulmonary arteries. Follow-up positron emission tomography scanning with fluorodeoxyglucose (FDG) revealed that the FDG uptake was greatly decreased in all the tumors, and the hormone levels were also decreased. CyberKnife is a safe and effective treatment option for the non-operative large advanced adrenocortical carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.55.6335 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nutritional support in children treated for advanced adrenocortical carcinoma.
Pediatr Surg Int
January 2025
Department of Surgery, St. Jude Children's Research Hospital, MS 133, 262 Danny Thomas Place, Memphis, TN, 38105, USA.
Purpose: Adrenocortical carcinoma (ACC) is a rare, aggressive pediatric malignancy. Advanced ACC requires multimodal treatment, including surgery and systemic chemotherapy including cisplatin, etoposide, doxorubicin, and mitotane. This is associated with significant gastrointestinal toxicity, resulting in many patients being unable to complete scheduled therapy.
View Article and Find Full Text PDFAn Unusual Case of Acute Abdomen With Jaundice.
Cureus
December 2024
Cardiology, University Clinics of Kinshasa, Kinshasa, COD.
Adrenocortical carcinomas are rare but aggressive tumors that are frequently discovered as incidentalomas. Secretory tumors often lead to endocrine abnormalities, namely cushingoid features, virilization, or feminization. Non-functioning tumors, on the other hand, can be completely dormant with an insidious course or cause malaise, weight loss, abdominal pain, etc.
View Article and Find Full Text PDFComparison between minimally invasive surgery and open surgery in managing localized adrenocortical carcinoma treatment: A retrospective propensity-matched study.
Int J Urol
January 2025
Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Background: It was controversial to use open surgery or minimally invasive surgery (MIS) for adrenocortical carcinoma (ACC). This retrospective study aimed to evaluate the impact on prognosis between MIS and open surgery in patients with clinical stage I-II ACC.
Methods: Patients with stage I-II ACC from December 2000 to October 2022 were retrospectively studied.
Adjuvant radiation therapy is not associated with a survival benefit after R0 resection in non-metastatic adrenocortical carcinoma.
Am J Surg
January 2025
Department of Surgery, 1300 York Avenue, Weill Cornell Medicine, New York, NY, 10065, USA.
The benefit of adjuvant radiation therapy (RT) in adrenocortical carcinoma (ACC) is not well characterized for those who undergo initial R0 surgical resection. Patients in the NCDB who underwent R0 resection were placed into two cohorts - those who underwent adjuvant RT and those who did not. 388 patients were identified with 51 receiving RT.
View Article and Find Full Text PDFDiagnostic challenges associated with adrenocortical neoplasms arising from adreno-hepatic fusion: a case report of two patients and a literature review.
Gland Surg
December 2024
Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Background: A right adrenal gland may present in the form of adreno-hepatic fusion (AHF), in which the adrenal cells are interspersed among the hepatocytes without septation. This rare, naturally-occurring phenomenon may be associated with preoperative misdiagnosis. We present two cases of adrenal tumor in patients with AHF that were misdiagnosed, despite thorough preoperative work-ups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!